Skip to main content
. 2019 Oct 29;10(59):6323–6333. doi: 10.18632/oncotarget.27259

Figure 1.

Figure 1

(A) The RET, RAS-RAF-MAPK pathway with sites of RXDX-105 inhibition in red. (B) RXDX-105 (CEP-32496) structure. (C) RXDX-105 inhibition of potential target kinases (adapted from [17]).